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A B S T R A C T
This study was undertaken to evaluate the effect of galanthamine, a new cholin-
esterase inhibitor on cognitive performances in 84 patients with various apoE genotype
and Alzheimer's disease (AD) during the six-month treatment. The diagnosis of AD was
made on the basis of NINCDS/ADRDN criteria. ApoE4 genotype was determined by
PCR procedure. The cognitive performance was assessed MMSE at baseline and six
months later. The difference among the groups was statistically analyzed by ANOVA
model and Pearson's 2-test. The MMSE at baseline in all completes was 18.0  3.73,
whereas the mean value of MMSE after 6 months was 16.4  5.61 indicating significant
deterioration (p < 0.01). Of the 84 patients, 14 (16%) were apoE4 homozygous, 41 (49%)
were heterozygous, whereas 29 (35%) were apoE4 negative. The significant number of
responders was observed among apoE4 homozygous patients (71%; 2 = 6.89; p = 0.032).
The subgroup of apoE4 homozygous patients with AD in its mild to moderate stage may
be considered as responders to galanthamine.
Introduction
Alzheimer's disease (AD) is progres-
sive degenerative disorder, characterized
by deficits in memory and cognition that
are associated with significant losses of
presynaptic cholinergic function in the
brain1. It has been speculated that cho-
linomimetics might improve cognitive
performances in patients with AD2. Ga-
lanthamine, a reversible acetylcholine-
sterase (AChE) inhibitor that can be iso-
lated from a number of different plant
sources, including daffodil bulbs, has been
used mainly in Eastern Europe as an an-
tagonist of non-depolarizing muscle rela-
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xants3. Animal studies indicate that ga-
lanthamine can improve learning and
memory performances4. Several clinical
studies have recently shown that galan-
thamine might be useful in the treatment
of cognitive decline in AD5,6, but there are
no biological markers which can predict
therapeutic response. Apolipoprotein E4
(apoE4) is a well known risk factor for the
onset of AD7. However, it seems that the
presence of apoE4 alleles have a negative
therapeutic effect in AD patients treated
by tacrine8.
The present study was undertaken to
evaluate the efficacy and tolerability of
galanthamine at a dosage level of 30 mg/
day during six month treatment of pa-
tients with various apoE genotypes who
suffered from mild to moderate AD.
Patients and Methods
Patients
Patients eligible for this study were
newly diagnosed patients of uncomplica-
ted, probable AD. The diagnosis of proba-
ble AD was made according to the criteria
outlined by National Institute of Neuro-
logical and Communicative Disorders and
Alzheimer's Disease and Related Disor-
ders Association (NINCDS-ADRDA crite-
ria)9 with no clinical or laboratory evi-
dence of a cause other than AD for their
dementia. Patients had scores on the Mi-
ni-Mental State Examination (MMSE)10
12–24, at both screening and baseline.
Patients with non-Alzheimer's dementia,
severe Alzheimer's dementia (MMSE <
12), and patients with Alzheimer's de-
mentia complicated by psychosis and sig-
nificant dysphasia were excluded from
the study. In addition, patients with con-
comitant diseases (chronic obstructive
airway disease, bradycardia, heart block,
active peptic ulcer, prostate disease) or
patients with concomitant medication
which might interfere with the effect of
galanthamine (anticholinergics, antide-
pressants, anxiolytics other than short
acting benzodiazepines for insomnia, an-
tiparkinsonics, NSAID, antiepileptics, ci-
metidine) were excluded from the study
prior to baseline. Patients who were known
to be hypersensitive to AChE inhibitors
were excluded. Patients were required to
have reliable caregiver. Written informed
consent was obtained from both the pa-
tient and from their caregiver.
Study design
This was a patient's name basis, 6-
month open label study. The trial was
conducted on outpatient basis. One hun-
dred and twenty-six patients were en-
rolled in the therapeutic study. Following
2–4 weeks of screening period, initially
one galanthamine hydrobromide tablet of
5 milligrams was administered daily. A
daily dose of galanthamine was increased
by 5 mg weekly, until optimal therapeutic
dose of 30 mg/day (two tablets) was achie-
ved. Patients who took less than 30 mg of
galanthamine daily more than 14 days
during the study were excluded from the
analysis.
Outcome measure was Mini Mental
Status Examination (MMSE) and it was
carried out by an independent neurolo-
gist who was not aware of the patient's
ApoE status before the treatment and at
6 months. Safety was assessed by physi-
cal examination, clinical laboratory tests,
adverse event monitoring, and evaluation
of the general health and well-being of
the patient every two weeks in the first
three-month period, then every four weeks
thereafter. Compliance was assessed ev-
ery four weeks, counting the tablets re-
turned.
Blood for ApoE genotypization was ta-
ken during the screening phase and was
analyzed from frozen samples by poly-
merase chain reaction (PCR) procedure
described by Hixon and Vernier11.
A statistical analysis was done in all
patients who completed a trial according
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to protocol. (Completes). Completes were
defined as patients who completed 6
months of treatment with at least 80%
compliance of study medication at month
6. ANOVA model was used for quantita-
tive analysis of efficacy variable. Qualita-
tive analysis (responders' rate) among
the groups was done by Pearson's 2-test.
Responders were defined as completes
who did not deteriorate at the end of
month 6.
Results
From 126 patients who started with
galanthamine treatment 84 (69%) pa-
tients completed 6 month treatment pe-
riod. The baseline characteristics of all
patients are shown in Table 1. In all groups,
there was an approximately equal pro-
portion of men and women. The distribu-
tion of mean age, duration of Alzheimer's
disease, a frequency of familiar history of
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TABLE 1









Number of patients: N (%) 126 62 (50.2%) 21 (16.7%) 43 (34.1%)








Sex (M/F) 65/61 35/27 9/12 22/21






















Number of patients (N) 84 41 (49%) 14 (16%) 29 (35%)








Sex (M/F) 42/42 23/18 5/9 14/15































End-point responders (N) 34 (40%) 15 (37%) 10 (71%) 9 (31%)
(2 = 6.89; p = 0.032)
** p < 0.01 (ANOVA model)
disease, and mean MMSE results did not
differ significantly across the three groups.
Twenty-nine patients did not complete
the study due to adverse events, whereas
13 patients were excluded due to lack of
compliance.
55 out of 84 completes (65%) were
apoE4 carriers, having at least one apoE4
allele. Fourteen patients (16%) were apoE4
homozygous and 41 (49%) were apoE4
heterozygous. Twenty-nine patients (35%)
were apoE4 negative. The frequency of
ApoE alleles among completes was e3 =
0.58; e4 = 0.41; e2 = 0.01.
The baseline characteristics of the
completes and non-completes were simi-
lar, and in all groups, there was no differ-
ence in sex, mean age, duration of Alzhei-
mer's disease, a frequency of familial his-
tory of disease. The mean MMSE results
did not differ significantly as well across
the three groups of completes and non-
completes.
As indicated in Table 1 the mean MMSE
score for all completes deteriorated after
six months. The mean value of MMSE at
baseline in all completes was 18.0  3.73
(range 12–24), whereas the mean value of
MMSE after 6 months was 16.4  5.61
(range 5–30). The deterioration was sta-
tistically significant (p<0.01). Among
three subgroups of patients, apoE4 nega-
tive patients and apoE4 heterozygous pa-
tients deteriorated after 6 months of
treatment. Only the subgroup of apoE4
homozygous improved slightly after six
months of treatment. The percentages of
responders were in apoE4 homozygous
71%, apoE heterozygous 37% and apoE
negative 31%. The difference in responders
rate among the genetic subgroups was
significant (2 = 6.89; p = 0.032), suggest-
ing that only apoE4 homozygous sub-
group of patients with Alzheimer's dis-
ease might be considered as responders
on galanthamine.
Discussion
This study suggests that 6-month
treatment with galanthamine does not
improve cognitive performances in patients
with mild to moderate AD. However, it
seems that apoE4 homozygous patients
with AD react favorably to other apoE
subgroups, and might be considered as
possible responders to galanthamine. This
result is not consistent with previously
reported effect of tacrine8, where apoE4
patients with AD were considered as non-
responders to tacrine. We believe that the
observed difference may be a clinically
important consequence of different type
of action of various AChE inhibitors12 on
cognitive performances. Galanthamine
acts differently than tacrine in at least
two directions. It is a direct nicotinic ago-
nist via different binding sites and inde-
pendently of the AChE activity13. In addi-
tion galanthamine is acting as a stimula-
tor of realizing of adrenocorticotrophic
hormone (ACTH)14 that could play role in
the anti-inflammatory process in AD. The
clinical implication of these pharmaco-
dynamic features of galanthamine on cog-
nitive performances in apoE4 homozy-
gous AD sufferers need to be tested in
randomized controlled clinical trials.
At present, galanthamine and other
ACE inhibitors as tacrine15, donepezil16
and rivastigmine17 are licensed for the
symptomatic treatment of mild to moder-
ate cognitive impairment, but the benefit
could be expected in only 20% of pa-
tients18. It has been proposed that treat-
ment of cognitive decline in AD should be
at least 6 months long to define respon-
ders19. We feel that the results of our
study will help in the early identification
of potential responders, thus avoiding un-
necessary exposure to AChE inhibitors.
There are several limitations to our
study. The open label uncontrolled clini-
cal studies are susceptible to bias, and
such results must be analyzed with care.
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Furthermore, MMSE may be insensitive
to change over short period of time in pa-
tients with AD. We wish to point out that
our study is preliminary involving a small
proportion of ApoE4 homozygous pa-
tients. Despite limitation, we believe that
our results are sufficiently encouraging
to warrant a larger prospective controlled
trial with more sensitive outcome mea-
sures like Alzheimer's disease assessment
scale (ADAS)20 or Clinical Interview Based
on the Impression of Change (CIBIC)21.
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APO-E GENOTIPIZIRANJE I ODGOVOR NA GALANTAMIN U
ALZHEIMEROVOJ BOLESTI – RETROSPEKTIVNA STUDIJA
S A @ E T A K
Svrha ovog istra`ivanja je bila procijeniti utjecaj galantamina, novog inhibitora ko-
linesteraze na kognitivne funkcije u 84 bolesnika s razli~itim ApoE genotipom i Alzhei-
merovom bolesti za vrijeme {estomjese~ne terapije. Dijagnoza AD postavljena je na
osnovu NINCDS/ADRDN kriterija. ApoE4 genotip je odre|en pomo}u PCR postupka.
Kognitivne funkcije bolesnika procijenjene su pomo}i MMSE na po~etku istra`ivanja i
nakon {est mjeseci. U statisti~koj analizi razlike me|u skupinama testirane su pomo}u
ANOVA-e i Pearsonovog 2-testa. Na po~etku istra`ivanja MMSE iznosio je 18,0  3,73,
dok je nakon {est mjeseci MMSE iznosio 16,4  5,61 {to indicira zna~ajno pogor{anje
(p<0,01). Od 84 bolesnika, 14 (16%) bili su ApoE4 homozigoti, 41 (49%) heterozigoti,
dok su 29 (35%) bolesnika bili ApoE4 negativni. Zna~ajan broj bolesnika koji su pozi-
tivno reagirali na primjenu galantamina zamije}eno je u skupini ApoE4 homozigotnih
bolesnika (71%; 2 =6,89; p=0,032). Rezultati studije sugeriraju pozitivan odgovor na
galantamin u skupini bolesnika koji su homozigoti za ApoE4 genotip.
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